title: Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.
abstract: OBJECTIVE
  To investigate the expressions of D2-40, CK19, galectin-3, VEGF, and EGFR in papillary thyroid carcinoma and their clinical significances.
  
  
  METHODS
  The expressions of D2-40, CK19, galectin-3, VEGF, and EGFR in 38 cases of papillary thyroid carcinoma and 12 cases of thyroid papillary hyperplasia were detected by immunohistochemical staining.
  
  
  RESULTS
  The positive expression rates of D2-40, CK19, Galectin-3, VEGF and EGFR in patients with papillary thyroid carcinoma were all significantly higher than those in patients with thyroid papillary hyperplasia (all P<0.05). The expressions of D2-40, VEGF, and EGFR in papillary thyroid carcinoma with lymph node metastasis were significantly higher than those without lymph node metastasis (P<0.05). The expressions of GK19 and galectin-3 showed no significant differences between the papillary thyroid carcinomas with and without lymph node metastasis (P>0.05).
  
  
  CONCLUSIONS
  The detection of D2-40, CK19, galectin-3, VEGF, and EGFR is helpful for the diagnosis and differential diagnosis of papillary thyroid carcinoma and thyroid papillary hyperplasia.
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Gong
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Xianjun
authors.initials: X
authors.lastname: Liu
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Han
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Yanping
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Weidong
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Chuanjia
authors.initials: C
authors.lastname: Li
authors.affiliation: Department of Pathology, the Central Hospital of Jilin City, Jilin 132011, China.
authors.forename: Jiang
authors.initials: J
authors.lastname: Xie
keywords: CK19; D2-40; EGFR; Thyroid neoplasms; VEGF; galectin-3; immunohistochemis; papillary carcinoma
references.citation: Endocr Relat Cancer. 2006 Dec;13(4):1173-83
references.pmid: 17158762
references.citation: Am J Pathol. 1995 Jul;147(1):9-19
references.pmid: 7541613
references.citation: World J Surg. 2010 Dec;34(12):3015-21
references.pmid: 20703465
references.citation: Pathologe. 2004 Sep;25(5):362-74
references.pmid: 15164222
references.citation: Mod Pathol. 2001 Apr;14(4):338-42
references.pmid: 11301350
references.citation: Histopathology. 2006 Jun;48(7):795-800
references.pmid: 16722927
references.citation: J Clin Endocrinol Metab. 2001 Feb;86(2):656-8
references.pmid: 11158026
references.citation: Endocr Pathol. 2003 Spring;14(1):55-60
references.pmid: 12746563
references.citation: Pharmacol Ther. 2009 Jul;123(1):117-41
references.pmid: 19374919
references.citation: Virchows Arch. 1997 Dec;431(6):407-13
references.pmid: 9428928
references.citation: J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23
references.pmid: 15240595
references.citation: Hum Pathol. 1999 Oct;30(10):1166-71
references.pmid: 10534163
references.citation: Thyroid. 2000 Apr;10(4):349-57
references.pmid: 10807064
references.citation: Acta Chir Iugosl. 2003;50(3):67-70
references.pmid: 15179758
references.citation: Exp Mol Pathol. 2011 Jun;90(3):312-7
references.pmid: 21335003
references.citation: Am J Pathol. 2010 May;176(5):2067-81
references.pmid: 20363921
references.citation: Histopathology. 2002 Sep;41(3):236-43
references.pmid: 12207785
references.citation: Histopathology. 2005 Apr;46(4):396-402
references.pmid: 15810951
references.citation: J Clin Endocrinol Metab. 2003 Aug;88(8):3694-9
references.pmid: 12915657
references.citation: Thyroid. 2009 Nov;19(11):1233-7
references.pmid: 19888861
references.citation: J Exp Ther Oncol. 2010;8(4):341-52
references.pmid: 21222366
references.citation: Am J Pathol. 2005 Mar;166(3):913-21
references.pmid: 15743802
references.citation: Pathology. 2011 Jan;43(1):40-7
references.pmid: 21240064
references.citation: APMIS. 2007 Aug;115(8):906-10
references.pmid: 17696946
references.citation: Int J Cancer. 1993 Aug 19;55(1):37-43
references.pmid: 8102129
references.citation: J Otolaryngol. 2003 Oct;32(5):319-22
references.pmid: 14974863
references.citation: Surgery. 1999 Dec;126(6):1056-61; discussion 1061-2
references.pmid: 10598188
references.citation: Int J Cancer. 2001 Sep 1;93(5):662-6
references.pmid: 11477575
references.citation: Endocr Pathol. 2010 Jun;21(2):80-9
references.pmid: 20198455